Akero Therapeutics Q2 EPS $(0.81) Beats $(0.90) Estimate; Akero's Cash, Cash Equivalents And Short And Long-term Marketable Securities As Of June 30, 2024, Were $848.3M
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics (NASDAQ:AKRO) reported a Q2 EPS of $(0.81), beating the analyst estimate of $(0.90). The company's cash and marketable securities as of June 30, 2024, were $848.3M.
August 09, 2024 | 11:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akero Therapeutics reported a Q2 EPS of $(0.81), beating the analyst estimate of $(0.90). The company's cash and marketable securities as of June 30, 2024, were $848.3M.
Akero Therapeutics' better-than-expected EPS indicates stronger financial performance than anticipated, which is likely to positively impact the stock price in the short term. Additionally, the substantial cash reserves provide a solid financial foundation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100